Swetha Kambhampati
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Swetha Kambhampati as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06575686 · Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular LymphomaCity of Hope Medical Center · suspended · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma · principal investigator
- Ph2NCT06112847 · Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular LymphomaCity of Hope Medical Center · active not recruiting · Follicular Lymphoma · principal investigator
- Ph2NCT05672251 · Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center · recruiting · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2004 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:56 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.J Clin Oncol · 2023182 citationsRCR 15.3
- 150 citationsRCR 4.4
- 135 citationsRCR 10.8
- Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.Blood Adv · 2022122 citationsRCR 8.5
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Br J Haematol · 200999 citationsRCR 2.2
- Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Leukemia · 201692 citationsRCR 2.4
- A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.Cancer Chemother Pharmacol · 201790 citationsRCR 2.9
- Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.Cancer Chemother Pharmacol · 201669 citationsRCR 2.2
- A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.Cancer Med · 201669 citationsRCR 2.1
- 66 citationsRCR 2.2